Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
Athenex (NASDAQ: ATNX), a biopharmaceutical company, will announce its third quarter 2022 corporate and financial update on November 3, 2022, before market opens. The management team will host a conference call at 8:00 a.m. Eastern Time. To join the call, dial 1-844-826-3033 (domestic) or 1-412-317-5185 (international) using the passcode 10171709. The live audio webcast will also be available on the company's Investor Relations website.
- Scheduled corporate and financial update indicates ongoing transparency with investors.
- Planned conference call provides investors with timely information on company's performance.
- None.
BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.
To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
Domestic: 1-844-826-3033
International: 1-412-317-5185
Passcode: 10171709
The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com
Tim McCarthy
LifeSci Advisors, LLC
Email: tim@lifesciadvisors.com
FAQ
When will Athenex announce its third quarter results?
What time is the Athenex conference call for third quarter results?
How can I participate in the Athenex earnings call?
What is the passcode for the Athenex conference call?
Where can I find the Athenex conference call replay?
